Experience in Treating Esophageal Cancer—September 12, 2001

Experience in Treating Esophageal Cancer—September 12, 2001

Wang Jiying, male, 57 years old, resident of Dongkou Second Community, Xiaohe Township, Zhangye City, farmer. On November 20, 1998, gastroscopy revealed mid-esophageal cancer, and barium meal examination confirmed the same. Pathological biopsy showed squamous cell carcinoma. After taking more than 100 doses of traditional Chinese medicine, all symptoms completely disappeared, and gastroscopy and barium meal examinations showed no abnormalities. The main herbal formula included: Sheng Dihuang, Shanjuyurou, Shanyao, Mudanpi, Fuling, Zexie, Chenpi, Yuanzhi, Xia Kucacao, Huangqi, Danshen, Danggui, Bai Shao, Zhi Ruxiang, Mo Yao, Chuanshanjia, Zaoguoci, Yujin, Zhebeimu, Sharen, Chutoukang, Helieti, Jineijin, and Sheng Yiren. The herbs were decocted in water and taken one dose daily. This formula incorporates elements from Liu Wei Di Huang Tang, Tuoli Xiaodu Dan, Qige San, along with Jineijin, Sheng Yiren, Chenpi, Yuanzhi, and Xia Kucacao. After taking 100 doses, all symptoms disappeared, and gastroscopy revealed that the tumor no longer existed. This case of cure was truly accidental: due to financial difficulties, the patient could not undergo surgery, radiation, or chemotherapy. It was like a blind cat catching a dead mouse and continuing to eat it—since the treatment proved effective, the patient persisted in self-administering over a hundred doses.

Modern Perspectives on Chronic Congestive Heart Failure—September 24, 2001

Heart failure represents the end-stage manifestation of all cardiovascular diseases. The common pathophysiological mechanism underlying cardiovascular diseases can lead to insufficient cardiac output. To compensate and increase cardiac output, the body activates compensatory mechanisms across various systems, including the autonomic nervous system and the renin-angiotensin system. Prolonged activation of these systems results in hyperplasia of neurotransmitters and enzymes in the endocrine system, generating free radicals that directly damage the heart and vascular endothelium, leading to ventricular hypertrophy, myocardial thickening, and further decline in cardiac function. Subsequent major changes include chronic sympathetic overactivity and increased catecholamine levels: ① Increased norepinephrine stimulates cyclic AMP (cAMP) signaling, causing elevated intracellular Ca^++++^, decreased high-energy phosphates, impaired mitochondrial function, and diminished myocardial function; ② Accelerated heart rate, enhanced myocardial contraction, increased oxygen consumption, and myocardial ischemia; ③ Alterations in systemic cytokine network regulation, achieved through factors such as tumor necrosis factor (TNF-α), interleukin-6 (IL-6), soluble TNF receptor I (sTNF-R I), and transforming growth factor β (TGF-β).

Autoimmune Hepatitis—September 28, 2001

This disease was formally named in recent years, with a higher incidence in Europe and America, accounting for 15% of chronic liver diseases. China is also a high-incidence area. Clinically, its presentation is similar to viral hepatitis, but the treatment approaches differ significantly. As early as 1950, someone proposed the concept of “autoimmune liver disease,” and in recent years, international conferences have officially designated it as “autoimmune hepatitis.” The disease is linked to genetic factors and tends to occur in susceptible populations and families. Certain triggers, such as infections, medications, and environmental factors, can provoke immune responses, leading to antigen-antibody complexes and other issues. Diagnosis relies on exclusion criteria: ① Hyperglobulinemia; ② Jaundice; ③ Hepatosplenomegaly; ④ Cirrhosis (possibly decompensated); ⑤ Rapid erythrocyte sedimentation rate; ⑥ Liver function impairment indistinguishable from other types of hepatitis.

Treatment primarily involves adrenal corticosteroids, which can complement hepatoprotective measures. The course of the disease is long, with an average corticosteroid regimen lasting 18 months, resulting in low five-year survival rates and poor prognosis. Currently, several antibody tests hold some diagnostic value, including ANA (anti-nuclear antibody), AMA (mitochondrial antibody), SMA (smooth muscle antibody), and LSP (liver-specific antibody). A positive result for any of these three antibodies can aid in diagnosis.

Acute Exacerbation of Chronic Obstructive Pulmonary Emphysema and Cor Pulmonale—October 26, 2001

The clinical manifestations of acute exacerbation of chronic obstructive pulmonary disease (COPD) include worsening cough, increased sputum production, and difficulty breathing. In severe cases, patients may experience rapid heart rate, heart failure, and respiratory failure. Most experts agree that the primary cause of these exacerbations is upper respiratory tract infection. Such infections typically involve viral and bacterial pathogens. According to foreign data, approximately 80% of COPD exacerbations are caused by viruses, mainly influenza virus (24%), syncytial virus (6.5%), rhinovirus (19%), coronavirus (14%), adenovirus (7%), and chlamydia (5–10%). Although bacterial infections are rarely the primary cause based on blood culture results, secondary infections are the biggest contributor to exacerbations. Therefore, when selecting antibiotics for treatment, both the initial viral infection and subsequent bacterial infections should be considered.

Weight Loss Effects of Nomethazine—October 29, 2001

This drug is also known as West Curve Ming. In the 21st century, obesity has become a serious global public health issue. The WHO has designated obesity as a priority area for prevention and control. Experts predict that within the next 10 years, the number of obese people in China may exceed 200 million. Nomethazine is a new weight-loss drug developed by Abbott Laboratories in the United States, approved by the FDA for its dual mechanism of action. The dual mechanism includes increasing satiety and reducing intake, as well as boosting energy expenditure and correcting metabolic imbalances in the body. After one year of use in six major hospitals in China, it has been proven that taking Nomethazine once daily for six months can significantly reduce body weight, waist circumference, and hip circumference, while also improving lipid and blood sugar profiles.

Key Diagnostic Points for Tuberculosis—October 31, 2001

Currently, there are three key diagnostic points for this disease: ① Chest X-ray; ② Tuberculin skin test; ③ Sputum smear and culture. Before these tests, anyone who experiences recurrent colds lasting more than two weeks, fatigue, cough, sputum production, fever, or blood in the sputum, especially those with a history of tuberculosis hypersensitivity—such as patients with nodular erythema, herpetic conjunctivitis, or keratitis—or those with tuberculosis-related conditions like diabetes, subtotal gastrectomy, pneumoconiosis, HIV positivity, or long-term use of immunosuppressive hormones, should be considered. Chest X-rays now classify tuberculosis into four types: ① Primary pulmonary tuberculosis, which includes past primary syndromes and bronchial lymph node tuberculosis. This type is characterized by ill-defined cloud-like or patchy shadows near the pleural border in the lung fields, along with lymphangitis and enlarged lymph nodes forming one or multiple groups, sometimes resembling dumbbells. ② Hematogenous disseminated pulmonary tuberculosis: acute, subacute, and chronic forms all fall under this category, with point-like or snowflake-like images appearing in the upper lung fields, making diagnosis possible. ③ Secondary pulmonary tuberculosis: this category encompasses infiltrative pulmonary tuberculosis, focal pulmonary tuberculosis, caseous pneumonia, and fibrocavitary pulmonary tuberculosis. ④ Tuberculous pleurisy. Previously, tuberculosis progression was divided into four stages: infiltration, dissolution and dissemination, absorption and improvement, and hardening and calcification. Now, it is classified according to exudation, caseation, cavitary lesions, and proliferation (with accompanying calcification), totaling four stages. Sputum smear acid-fast staining: if fewer than 10 “+” signs are found in 100 fields, it is rated as “+”; if fewer than 10 “++” signs are found in 10 fields, it is rated as “++”; if fewer than 10 “+++” signs are found in one field, it is rated as “+++”; and if more than 10 “++++” signs are found in each field, it is rated as “++++.”

Interpretation of Sputum Culture Tests—October 31, 2001

No colony growth (-), one-quarter of the slant area (+), one-half of the slant area (++), three-quarters of the slant area (+++), and the entire slant area (++++).

Evaluation of the Tuberculin Skin Test—October 31, 2001

A positive tuberculin skin test (OT, PPD) confirms the diagnosis, while a weakly positive result may be a false positive, and a negative result rules out the disease. However, in clinical practice, there are exceptions: for example, small cell lung cancer may produce a positive or strongly positive tuberculin skin test result. Malignant lymphoma also often shows a strongly positive reaction. Additionally, in cases of tuberculous pleurisy or early acute miliary tuberculosis, the tuberculin skin test may initially yield a negative result.

Treatment of Tuberculosis—November 1, 2001

Commonly used medications include isoniazid (INH), rifampicin (RFP), pyrazinamide (PZA), and ethambutol (EMB). The treatment course lasts six months; if drugs without Z or R are used, the duration should be extended to nine to twelve months. Tuberculosis treatment is generally divided into an intensive phase and a consolidation phase. The former involves combining three to four drugs for eight weeks to eradicate multiple bacterial strains, while the latter combines two to three drugs for four months to achieve complete recovery. The national tuberculosis conference has agreed on the following scheme: ① 2H3R3Z3/4H3R3; ② 2H3R3Z3E3/4H3R3.

Century-Long Prospects for Calcium Channel Blockers—November 8, 2001

In the 1960s, Fleckenstein first discovered the anti-angina effect of calcium channel blockers (CCB), which is based on blocking myocardial-dependent contractions. Later, with the widespread clinical use of nifedipine, people found that the drug had a short half-life and its blood concentration could not remain stable, prompting efforts to develop sustained-release and controlled-release formulations. Five years ago, there was debate over whether CCBs could cause serious complications. This question led to a six-month-long controversy due to erroneous conclusions drawn from a small number of cases. Ultimately, after careful arbitration by the FDA and WHO, a positive conclusion was reached.

Pharmacological effects of CCBs: Unlike digitalis preparations, CCBs have a negative inotropic effect, which greatly reduces myocardial oxygen consumption and thus protects the heart. Another major effect is their negative chronotropic action, which is similar to the mechanism of digitalis. In addition, the most distinctive feature of CCBs is their ability to reverse myocardial hypertrophy. In hypertensive patients, left ventricular hypertrophy is a long-term adaptation to high blood pressure, driven by increased intracellular free calcium ions, which promote myocardial thickening. CCBs, however, inhibit calcium influx, reducing the factors that promote myocardial hypertrophy, dilate blood vessels, counteract smooth muscle proliferation, and reduce atherosclerosis. Five years ago, American scholars raised the question of whether CCBs could exacerbate coronary heart disease, tumors, upper gastrointestinal bleeding, and other serious conditions, sparking widespread debate. China conducted a study involving 2,394 hypertensive patients, using nicardipine as the first-line treatment, and followed up for four years. The results showed that the drug significantly reduced overall mortality, cardiovascular events, stroke, and coronary heart disease, proving that calcium channel blockers can indeed achieve the goals of lowering blood pressure, preventing coronary heart disease, and preventing stroke, while remaining safe and having long-term efficacy. This debate has now come to an end, and CCBs are being widely used around the world with unstoppable momentum.